title: A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.
abstract: Cysteine-conjugated antibody-drug conjugates (ADCs) are manufactured using controlled partial reduction and conjugation chemistry with drug payloads that typically occur in intervals of 0, 2, 4, 6, and 8. Control of heterogeneity is of particular importance to the quality of ADC product because drug loading and distribution can affect the safety and efficacy of the ADC. Liquid chromatography ultra-violet (LC-UV)-based methods can be used to acquire the drug distribution profiles of cysteine-conjugated ADCs when analyzed using hydrophobic interaction chromatography (HIC). However, alternative analysis techniques are often required for structural identification when conjugated drugs do not possess discrete ultra-violet absorbance properties for precise assessment of the drug-to-antibody ratio (DAR). In this study, multidimensional chromatography was used as an efficient method for combining non-compatible techniques, such as HIC, with analysis by mass spectrometry (LC/LC/QTOF-MS) for rapid on-line structural elucidation of species observed in HIC distribution profiles of cysteine-conjugated ADCs. The methodology was tested using an IgG1 mAb modified by cysteine conjugation with a non-toxic drug mimic. Structural elucidation of peaks observed in the HIC analysis (1(st) dimension) were successfully identified based on their unique sub-unit masses via mass spectrometry techniques once dissociation occurred under denaturing reversed phase conditions (2(nd) dimension). Upon identification, the DAR values were determined to be 2.83, 4.44, and 5.97 for 3 drug load levels (low-, medium-, and high-loaded ADC batches), respectively, based on relative abundance from the LC-UV data. This work demonstrates that multidimensional chromatography coupled with MS, provides an efficient approach for on-line biotherapeutic characterization to ensure ADC product quality.
authors: a Biopharmaceutical Business Operations, Waters Corporation ; Milford , MA USA.
authors: Robert E
authors: RE
authors: Birdsall
authors: a Biopharmaceutical Business Operations, Waters Corporation ; Milford , MA USA.
authors: Henry
authors: H
authors: Shion
authors: b Pfizer Bioprocess Research & Development, Pfizer Inc ; Pearl River , NY USA.
authors: Frank W
authors: FW
authors: Kotch
authors: c Pfizer Analytical Research & Development, Pfizer Inc ; Pearl River , NY USA.
authors: April
authors: A
authors: Xu
authors: d Pfizer Analytical Research & Development, Pfizer Inc ; Andover , MA USA.
authors: Thomas J
authors: TJ
authors: Porter
authors: a Biopharmaceutical Business Operations, Waters Corporation ; Milford , MA USA.
authors: Weibin
authors: W
authors: Chen
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry*; D002853:Chromatography, Liquid / Q000379:methods*; D003545:Cysteine / Q000737:chemistry*; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry* / Q000276:immunology; D007074:Immunoglobulin G / Q000737:chemistry; D013058:Mass Spectrometry / Q000379:methods*; D015203:Reproducibility of Results; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007074:Immunoglobulin G; D003545:Cysteine
keywords: 2DLC; ADC; LC/LC/MS; antibody-drug-conjugate; cysteine-drug-conjugate; drug-antibody-ratio; multidimensional chromatography; positional isomers